Studies have reported that dopamine can promote the progression of glioma by binding to dopamine receptor 2 (DRD2), which is highly expressed in GBM cells, activating the expression of epidermal growth factor receptor (EGFR), and promoting the phosphorylation of mitogen-activated protein kinase (MAPK) (73). Here, EGFR is linked to glioblastoma.